| 17.95 0.93 (5.46%) | 12-10 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.65 |
1-year : | 26.46 |
| Resists | First : | 19.39 |
Second : | 22.65 |
| Pivot price | 17.59 |
|||
| Supports | First : | 17.06 |
Second : | 15.61 |
| MAs | MA(5) : | 18.14  |
MA(20) : | 17.64 |
| MA(100) : | 21.6 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 64.6 |
D(3) : | 72.7 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 36.9 | Low : | 15.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SMMT ] has closed below upper band by 38.6%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.1 - 18.19 | 18.19 - 18.27 |
| Low: | 16.61 - 16.71 | 16.71 - 16.79 |
| Close: | 17.8 - 17.96 | 17.96 - 18.09 |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Fri, 05 Dec 2025
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fri, 05 Dec 2025
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - Finviz
Tue, 02 Dec 2025
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance
Wed, 19 Nov 2025
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT) - Seeking Alpha
Tue, 18 Nov 2025
Wolfe Research Initiates Coverage of Summit Therapeutics (SMMT) with Peer Perform Recommendation - Nasdaq
Mon, 03 Nov 2025
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 744 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 86 (%) |
| Held by Institutions | 14.4 (%) |
| Shares Short | 31,240 (K) |
| Shares Short P.Month | 32,270 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -152.9 % |
| Return on Equity (ttm) | -292.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -270 (M) |
| Levered Free Cash Flow | 74 (M) |
| PE Ratio | -14.37 |
| PEG Ratio | 0 |
| Price to Book value | 69.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -49.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|